Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Novartis and Bristol Myers followed suit, beating second-quarter estimates for both earnings and revenues. Merck beat estimates for earnings while meeting the same for revenues in the second quarter. Meanwhile, AstraZeneca met estimates for earnings while beating the same for revenues in the second quarter. French drugmaker Sanofi came out with disappointing second-quarter results as it missed estimates for both earnings and sales.
Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies.
Per the Earnings Trends report, as of July 29, 33.3% of the companies in the Medical sector — representing 40.9% of the sector's market capitalization — reported quarterly earnings. Out of these, 80% surpassed earnings estimates, while 95% beat the same for revenues. Earnings declined 10.4% year over year, while revenues rose 11.9%. Overall, second-quarter earnings of the Medical sector are expected to remain flat, while sales are projected to rise 8.7% from the year-ago quarter.
Let's see how things have shaped up for these companies ahead of their earnings announcements.
Pfizer
PFE's performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 43.49%, on average. In the last reported quarter, the company delivered an earnings surprise of 43.75%.
The Zacks Consensus Estimate for second-quarter sales and earnings stands at $13.78 billion and 58 cents per share, respectively.
Pfizer has an Earnings ESP of +1.43% and a Zacks Rank #3 (Hold), indicating a beat this time around. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Higher sales of Pfizer's products like Vyndaqel family, Padcev, Lorbrena and Nurtec are expected to have offset softer sales of some key products like Prevnar, Xeljanz, Eliquis and Ibrance in the second quarter. The Medicare Part D redesign under the Inflation Reduction Act (IRA) is likely to have impacted U.S. revenues, particularly sales of higher-priced drugs, including Vyndaqel, Ibrance, Xtandi and Xeljanz.
PFE is scheduled to report second-quarter results on Aug. 5, before the opening bell.
Pfizer Inc. Price and EPS Surprise
Eli Lilly
LLY's performance has been mixed, with the company exceeding earnings expectations in two of the trailing four quarters and missing the same on the remaining two occasions. It delivered a four-quarter earnings surprise of 6.69%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 5.11%.
The Zacks Consensus Estimate for second-quarter sales and earnings stands at $14.75 billion and $5.61 per share, respectively.
LLY has an Earnings ESP of +0.18% and a Zacks Rank #3, indicating a positive earnings surprise this time around.
In the second quarter, Lilly's top-line growth is likely to have been driven by its popular GLP-1 drugs, diabetes drug Mounjaro and weight loss medicine, Zepbound, driven by high demand trends.
Higher demand and volume growth for Lilly's other key drugs like Emgality, Jardiance, Olumiant, Taltz and Verzenio are likely to have provided top-line support in the second quarter, driven by increased demand trends.
LLY is scheduled to report second-quarter results on Aug. 7, before the opening bell.
Amgen
AMGN's performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 8.34%, on average. In the last reported quarter, the company delivered an earnings surprise of 17.79%.
The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $8.86 billion and $5.26 per share, respectively.
AMGN has an Earnings ESP of +0.56% and a Zacks Rank #3, indicating a positive surprise this time around.
Amgen's product sales in the second quarter are likely to have been driven by strong volume growth of products like Evenity, Repatha and Blincyto, among others. However, prices of most products are expected to have declined due to higher rebates to support expanded access.
Higher volumes of newer drugs like Tezspire and Tavneos are also expected to have contributed to top-line growth, driven by an increase in new patient volume.
AMGN is scheduled to report second-quarter results on Aug. 5, after market close.
Gilead Sciences
GILD's performance has been mixed, with earnings beating estimates in three of the trailing four quarters and missing the same on the remaining occasion. The company delivered a four-quarter earnings surprise of 16.48%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 0.55%.
The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $6.95 billion and $1.95 per share, respectively.
GILD has an Earnings ESP of +0.58% and a Zacks Rank #3, indicating a positive surprise this time around.
Gilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. HIV sales were up in the first quarter despite the impact of the new Medicare Part D model implementation due to increased demand for Biktarvy and Descovy. This trend has most likely prevailed in the second quarter as well.
Higher demand for viral hepatitis medicines has likely boosted sales of the Liver Disease portfolio in the second quarter.
GILD is scheduled to report second-quarter results on Aug. 7, after market close.
Novo Nordisk
NVO's performance has been mixed, with earnings beating estimates in one of the trailing four quarters, meeting the same once and missing the same on the remaining two occasions. The company delivered a four-quarter earnings surprise of 0.02%, on average. In the last reported quarter, the company delivered in-line earnings.
The Zacks Consensus Estimate for sales and earnings for the second quarter is pegged at $11.79 billion and 93 cents per share, respectively.
NVO has an Earnings ESP of +0.22% and a Zacks Rank #4 (Sell).
Last week, NVO lowered its 2025 outlook for both sales and operating profit growth. The company expects sales to rise 8-14% in 2025, down from its earlier forecast of 13-21%. Similarly, it revised its operating profit growth projection to 10-16%, down from the prior range of 16-24%. NVO cited weaker-than-expected momentum in key markets for its semaglutide-based obesity and diabetes drugs, Wegovy and Ozempic, as reasons for the guidance cut.
Also, during the same time, Novo Nordisk reported preliminary earnings per American Depositary Receipt of 91 cents (DKK 5.96), which missed the Zacks Consensus Estimate of 94 cents. The company said its sales for the second quarter have increased 18% at a constant exchange rate.
Novo Nordisk is set to release results on Aug. 6, before the opening bell.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
28 minutes ago
- National Post
Samsara to Announce Second Quarter Fiscal Year 2026 Financial Results on September 4, 2025
SAN FRANCISCO — Samsara Inc. ('Samsara') (NYSE: IOT), the pioneer of the Connected Operations® Platform, today announced that it will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, after the U.S. market closes on Thursday, September 4, 2025. Samsara will host a live webcast that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results. THIS CONTENT IS RESERVED FOR SUBSCRIBERS Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. SUBSCRIBE FOR MORE ARTICLES Enjoy the latest local, national and international news. Exclusive articles by Conrad Black, Barbara Kay and others. Plus, special edition NP Platformed and First Reading newsletters and virtual events. Unlimited online access to National Post. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors : Samsara's Second Quarter Fiscal Year 2026 Financial Results : Thursday, September 4, 2025 : 2:00 p.m. Pacific time (5:00 p.m. Eastern time) A webcast replay will be accessible from the Samsara investor relations website at The press release will be available on the Samsara investor relations website prior to the commencement of the event. Samsara (NYSE: IOT) is the pioneer of the Connected Operations® Platform, which enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world's leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. The company's mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy. View source version on
Globe and Mail
28 minutes ago
- Globe and Mail
Dow leaps 585 points as US stocks win back most of Friday's wipeout
NEW YORK (AP) — U.S. stocks rallied on Monday and won back most of their sharp loss from last week, when worries about how President Donald Trump's tariffs may be punishing the economy sent a shudder through Wall Street. The S&P 500 jumped 1.5% to follow up its worst day since May with its best since May. The Dow Jones Industrial Average climbed 585 points, or 1.3%, and the Nasdaq composite leaped 2%. Idexx Laboratories helped lead the way and soared 27.5% after the seller of veterinary instruments and other health care products reported a stronger profit for the spring than analysts expected. It also raised its forecast for profit over the full year. Tyson Foods likewise delivered a bigger-than-expected profit for the latest quarter, and the company behind the Jimmy Dean and Hillshire Farms brands rose 2.4%. They helped make up for a nearly 3% loss for Berkshire Hathaway after Warren Buffett's company reported a drop in profit for its latest quarter from a year earlier. The drop-off was due in part to the falling value of its investment in Kraft Heinz. The pressure is on U.S. companies to deliver bigger profits after their stock prices shot to record after record recently. The jump in stock prices from a low point in April raised criticism that the broad market had become too expensive. Stocks are coming off their worst week since May not so much because of that criticism but because of worries that Trump's tariffs may be hitting the U.S. economy following a longer wait than some economists had expected. Job growth slowed sharply last month, and the unemployment rate worsened to 4.2%. Trump reacted to Friday's disappointing jobs numbers by firing the person in charge of compiling them. He also continued his criticism of the Federal Reserve, which could lower interest rates in order to pump adrenaline into the economy. The Fed has instead been keeping rates steady this year, in part because lower rates can send inflation higher, and Trump's tariffs may be set to increase prices for U.S. households. Friday's stunningly weak jobs report did raise expectations on Wall Street that the Fed will cut interest rates at its next meeting in September. That caused Treasury yields to slump in the bond market, and they eased a bit more on Monday. The yield on the 10-year Treasury slipped to 4.19% from 4.23% late Friday. 'In our view, if the Fed starts to cut rates at its September meeting, we believe this would be supportive for markets,' according to David Lefkowitz, head of US equities at UBS Global Wealth Management. Such hopes, combined with profit reports from big U.S. companies that have largely come in better than expected, could help steady a U.S. stock market that may have been due for some turbulence. Before Friday, the S&P 500 had gone more than a month without a daily swing of 1%, either up or down. This upcoming week may feature fewer fireworks following last week's jobs report and profit updates from some of Wall Street's most influential companies. This week's highlights will likely include earnings reports from The Walt Disney Co., McDonald's and Caterpillar, along with updates on U.S. business activity. On Wall Street, American Eagle Outfitters jumped 23.6% after Trump weighed in on the debate surrounding the retailer's advertisements, which highlight actor Sydney Sweeney's great jeans. Some critics thought the reference to the blonde-haired and blue-eyed actor's 'great genes' may be extolling a narrow set of beauty standards. 'Go get 'em Sydney!' Trump said on his social media network. Wayfair climbed 12.7% after the retailer of furniture and home decor said accelerating growth helped it make more in profit and revenue during the spring than analysts expected. Tesla rose 2.2% after awarding CEO Elon Musk 96 million shares of restricted stock valued at approximately $29 billion. The move could remove potential worries that Musk may leave the company. CommScope soared 86.3% after reaching a deal to sell its connectivity and cable business to Amphenol for $10.5 billion in cash, while Amphenol rose 4.1%. They helped offset a 15.6% loss for On Semiconductor, which only matched analysts' expectations for profit in the latest quarter. The company, which sells to the auto and industrial industries, said it's beginning to see 'signs of stabilization' across its customers. All told, the S&P 500 rose 91.93 points to 6,329.94. The Dow Jones Industrial Average climbed 585.06 to 44,173.64, and the Nasdaq composite leaped 403.45 to 21,053.58. In stock markets abroad, indexes rose across much of Europe and Asia. South Korea's Kospi rose 0.9%, and France's CAC 40 climbed 1.1%, while Japan's Nikkei 225 was an outlier with a drop of 1.2%.
Globe and Mail
28 minutes ago
- Globe and Mail
Why Rocket Lab Might Be the Next SpaceX -- but With a Catch
Rocket Lab (NASDAQ: RKLB) is up 800% in just 12 months, riding a wave of hype, defense contracts, and bold ambitions to challenge SpaceX. But with no profits and an extreme valuation, is it a breakthrough or a bubble? Watch this before you invest. Stock prices used were the market prices of Aug. 4, 2025. The video was published on Aug. 4, 2025. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Should you invest $1,000 in Rocket Lab right now? Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab. The Motley Fool has a disclosure policy. Rick Orford
